Core Insights - Two phase III clinical trial results regarding the drug "Marsduptide" for blood sugar reduction and weight loss have been published in the prestigious journal "Nature," marking a significant achievement for China's pharmaceutical research [1][4]. Group 1: Clinical Research Findings - The published studies include the DREAMS-1 trial, which focuses on monotherapy for type 2 diabetes patients, and the DREAMS-2 trial, which examines the drug's use in combination with oral hypoglycemic agents [4]. - The results indicate that Marsduptide outperforms both placebo and Dulaglutide (1.5mg) in terms of blood sugar control and weight loss, while also improving various cardiovascular, liver, and kidney-related metrics [6]. Group 2: Drug Mechanism and Development - Marsduptide is the first and only GCG/GLP-1 dual-target weight loss and blood sugar reduction drug approved for market by Innovent Biologics. It works by enhancing insulin secretion and promoting satiety through GLP-1 receptor activation, while GCG receptor activation aids in fat oxidation and energy expenditure [5]. - The drug has been approved in China for both diabetes and weight loss indications and has undergone seven phase III studies covering diabetes, obesity, and related complications. Notably, the phase I study in adolescents showed significant weight loss and metabolic benefits [5].